“Tumor Paint” gets FDA approval for human clinical trials

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

A Seattle-based company that is conducting cancer research, has reached an important milestone.
Blaze Bioscience, Inc. has received the go-ahead to begin clinical trials on humans for its Tumor Paint. The paint is designed to allow surgeons to spot cancerous tissue during surgery by making it glow fluorescent under laser light.
The paint is not intended to cure cancer, but it can help surgeons spot and remove malignant tumors.
“So when it binds to the cancer cell, it flips inside the cancer cell and makes them light up so the surgeon can see them in real-time while they are operating,” said Jim Olsen, M.D., Pediatric Oncologist with Blaze Bioscience.
He says it’s been a long road to reach this goal.
“Through bake sales and golf tournaments and chili cook offs, they raised $8-million and that funded the early discovery work that allowed tumor paint to get FDA approval for human trials this week,” Olsen added.
So far, the Tumor Paint has only been tested on lab rats and dogs with cancer, but the results were very promising.
Blaze Bioscience, Inc. will now begin recruiting patients in the U.S. and Australia for its clinical trial. The researchers say this could revolutionize cancer treatment.
For more information, visit this website, http://www.blazebioscience.com

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.